

## Effects of *n*-3 very-long-chain polyunsaturated fatty acids on bone mineralization

Martina Torrissen <sup>1,2,3,\*</sup>, Elisabeth Ytteborg <sup>1</sup>, Harald Svensen, Tone-Kari Østbye <sup>1</sup>, Gerd Berge <sup>1</sup>, Sjur Reppe <sup>4,5,6</sup>, Aleksei Krasnov <sup>1</sup> and Bente Ruyter <sup>1,3</sup>

<sup>1</sup>Nofima (Norwegian Institute of Food, Fisheries and Aquaculture Research), 1432 Ås, Norway

<sup>2</sup>Epax Norway, 6006 Ålesund, Norway

<sup>3</sup>NMBU (Norwegian University of Life Sciences), 1433 Ås, Norway

<sup>4</sup>Department of Medical Biochemistry, Oslo University Hospital, 9424 Oslo, Norway

<sup>5</sup>Department of Plastic and Reconstructive Surgery, Oslo University Hospital, Oslo, Norway

<sup>6</sup>Unger-Vetlesen Institute, Lovisenberg Diaconal Hospital, Oslo, Norway

\*Correspondence: [martina.torrissen@gmail.com](mailto:martina.torrissen@gmail.com)

Running title: Effects of *n*-3 very-long-chain polyunsaturated fatty acids on bone mineralization

**Keywords:** very-long-chain polyunsaturated fatty acids (VLC-PUFA); polyunsaturated fatty acid; omega-3 fatty acids; bone, mineralization.



This peer-reviewed article has been accepted for publication but not yet copyedited or typeset, and so may be subject to change during the production process. The article is considered published and may be cited using its DOI

10.1017/S0007114524003052

The British Journal of Nutrition is published by Cambridge University Press on behalf of The Nutrition Society

**Abstract:**

The present study investigated whether dietary *n*-3 very-long-chain PUFAs (*n*-3 VLC-PUFAs) could increase skin and bone mineralization in Atlantic salmon (*Salmo salar*) *in vivo* and examined their potential effects on human osteoblast proliferation and differentiation *in vitro*. Atlantic salmon were fed different dietary levels of *n*-3 VLC-PUFA, and changes in tissue *n*-3 VLC-PUFA composition, skeletal morphology, skin and bone mineral content, bone mineral density (BMD), and gene expression patterns were examined. Additionally, *in vitro* experiments using human foetal osteoblast cells were conducted to investigate the potential influence of *n*-3 VLC-PUFA supplementation on cell proliferation, osteogenic differentiation, and cytokine expression. The results demonstrated that increasing the dietary levels of *n*-3 VLC-PUFAs increased the mineral content of vertebrae and BMD in salmon, with subtle yet significant impacts on the expression of genes involved in bone-related processes. Furthermore, *in vitro* experiments showed a potential contextual influence of *n*-3 VLC-PUFA supplementation on gene expression of osteogenic markers and cytokine expression. Our findings indicate for the first time that *n*-3 VLC-PUFAs may influence processes related to bone mineralization.

**Abbreviations:** *n*-3, omega-3; *n*-3 VLC-PUFAs, *n*-3 very-long-chain PUFAs; BMD, bone mineral density; PUFAs, polyunsaturated fatty acids; *n*-6, omega-6; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; MUFA, monounsaturated fatty acid; ND, not detected; SFAs, saturated fatty acids; Ctr, Control; L-VLC, Low-VLC; I-VLC, Intermediate-VLC; MH-VLC, Medium-High-VLC; H-VLC, High-VLC; CT, computed tomography; CS, micro-CT scanner; CTan, CT-analyser; hFOB 1.19, human foetal osteoblast cell line; BSA, bovine serum albumin; PBS, phosphate-buffered saline; BW, body weight; SEM, standard error of the mean; SGR, specific growth rate; TGC, thermal growth coefficient; Y, yttrium; P, phosphorus; Ca, calcium; Mg, magnesium; Zn, Zinc; DM, dry matter; HD, hyper-dense; DEGs, differentially expressed genes; Bcl6, B-cell lymphoma 6a; mmp13, collagenase 3; MK167, Ki-67; MYBL2, MYB protooncogene like 2; CCNB1, cyclin B1; PCNA, proliferating nuclear antigen; RUNX2, runt-related transcription factor 2; BGLAP, bone gamma-carboxyglutamate protein; COL1A1, collagen type 1 alpha 1 chain; B1, batch 1.

## 1. Introduction

Osteoporosis is a major health problem in post-menopausal women and in the elderly population [1]. It may cause morbidity and mortality, and an economic burden on society [1]. While there are therapies to treat osteoporosis, of which bisphosphonates, recombinant human parathyroid hormone, and humanized antibodies are the most effective [2], they may have adverse side effects [3, 4]. Diets and lifestyles that minimize bone loss are therefore preferred to reduce and prevent osteoporosis, as well as the side effects caused by these therapies.

Increased consumption of dietary omega-3 (*n*-3) polyunsaturated fatty acids (PUFAs) has been shown to increase bone strength via different mechanisms in different species. In post-menopausal mice, *n*-3 fatty acids have been shown to protect against bone loss [5-7]. Furthermore, *n*-3 fatty acids from oily fish have been shown to decrease levels of cytokines, such as IL-1 $\beta$ , IL-5, and TNF- $\alpha$ , and reduce bone resorption [8]. Consumption of *n*-3 fatty acids has further been shown to protect against age-related bone loss, and high intake of oily fish, rich in *n*-3 fatty acids, has been associated with greater bone mass and lower risk of osteoporosis in postmenopausal women [9]. In a study conducted by Lage et al. [10], a lack of essential *n*-3 fatty acids demonstrated potential effects on bone mineralization, and a comprehensive review by Pino and Rodríguez [11] highlighted the relevance of fatty acid composition in bone health. Additionally, several experimental studies have revealed that *n*-3 fatty acids promote mineral deposition in bone and provide strength to the bone by inhibiting bone resorption with a potential reversal of bone loss [12]. Furthermore, in Atlantic salmon (*Salmo salar*), unspecialised precursor cells showed improved differentiation *in vitro* when supplemented with *n*-3 PUFAs [13]. On the other hand, excess consumption of omega-6 (*n*-6) fatty acids may have a negative effect on bone formation by promoting the differentiation of mesenchymal stem cells to adipocytes instead of osteoblasts, which is a main cause of age-related bone loss [14].

While *n*-3 PUFAs have been extensively studied for their various roles in physiological processes, *n*-3 very-long chain polyunsaturated fatty acids (VLC-PUFAs), defined as fatty acids with a carbon chain length of  $\geq 24$ , are less well understood. These fatty acids are characterized by their longer carbon chains, but are distinct from the well-studied *n*-3 PUFAs eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) [15]. Several studies have

suggested that VLC-PUFAs may have specific functions in various tissues, as evidenced by different pathologies when they are absent [16]. However, the exact nature of these functions remains unclear [15-19].

We previously reported that dietary supplementation with an *n*-3 VLC-PUFA concentrate in the early life stages of Atlantic salmon increased mineralization and maturation of the scales of the skin. The scale development bears many similarities to development of bone tissue in vertebrates, including mammals [20]. In fact, there are several physiological and morphological features shared between teleost scales and mammalian and fish bone [21], sharing several matrix proteins such as type I collagen, bone  $\gamma$ -carboxyglutamic acid protein, and osteonectin [21-23]. The cells osteoblasts and osteoclasts, responsible for building the bone matrix in both mammals and fish are also shown to have similar functions in both species. Studies of processes related to bone development in Atlantic salmon can thereby provide important knowledge of relevance for human research on bone development [21, 24]. Furthermore, Elov14-like elongase in Atlantic salmon has been identified as a critical enzyme in the biosynthesis of very-long-chain fatty acids (VLC-FAs), with mRNA transcripts abundant in the eye, brain, and testes – similar to what is observed in mammals [25]. This further underscores the relevance of Atlantic salmon as a model for studying VLC-PUFAs and their potential roles in bone development, with implications for understanding similar processes in humans.

The present study investigated the potential of *n*-3 VLC-PUFAs to influence bone mineralization following a 5-week dose-response feeding trial in Atlantic salmon and the effects of *n*-3 VLC-PUFA on the proliferation and differentiation of the human foetal osteoblast cell line, hFOB 1.19. Both the fish diets and growth media were designed to include increasing levels of VLC-PUFAs to capture changes related to bone development, such as stimulation of cell proliferation, osteogenic differentiation, and mineralization. Several studies have shown associations between the consumption of LC-*n*-3 fatty acids and beneficial effects on bone health; however, to our knowledge, no studies have investigated the effects of the novel *n*-3 VLC-PUFAs on bone health.

## 2. Materials and Methods

### 2.1. Production of *n*-3 VLC-PUFA concentrates

Two different *n*-3 VLC-PUFA concentrates were made from an anchovy fish oil distillation fraction by hydrolysis, precipitation with LiOH, and distillation [26] as previously described [27]. Both concentrates were produced by Epax Norway AS (Aalesund, Norway). The fatty acid composition of the concentrates used in the salmon feeding trial and cell culture experiments are presented in Table 1. In the feeding trial and cell culture experiments, different concentrates were used to isolate the effects of *n*-3 VLC-PUFAs from those of other fatty acids and to increase the concentration of *n*-3 VLC-PUFAs, allowing for the addition of smaller volumes in the *in vitro* studies. In the feeding trial, the salmon diet already contained a variety of other fatty acids, which meant there was no need for a concentrate devoid of saturated fatty acids,  $\leq 22$ -carbon monounsaturated fatty acids (MUFAs), and PUFAs. Consequently, the composition of the concentrate used in the feeding trial differed from that used in the cell culture experiments, which required a more specific formulation to accurately assess the effects of *n*-3 VLC-PUFAs in a controlled environment.

### 2.2. Atlantic salmon feeding trial

Atlantic salmon ((SAL-1-22), Salmo Breed) were housed in freshwater tanks (100-L,  $n = 100$  fish per tank) at Nofima's Aquaculture research station for sustainable aquaculture at Sunndalsøra, Norway. The fish were maintained in conditions of 24 h light and temperature controlled to 12.5 °C ( $\pm 0.5$  °C). The water flow was set to 5 L/min and oxygen was adjusted to 85%–100% by adding oxygen to the water holding tank when needed. Mortality was recorded daily and the trial lasted 5 weeks.

One experimental extruded basal diet without lipid addition were produced at the Nofima's aquafeed technology centre (Bergen, Norway), with a pellet size of 1.5 mm (similar to a method previously described by Bogevik et al., 2021 [28]). The basal diet was added the inert mineral marker yttrium (Y) which is not digested. This marker enable analyses of mineral digestibility/uptake in intestine according to the method described by Hatlen et al., 2015 [29]. The basal diet was then divided into five equal batches. The five diets were made by coating of each extruded basal feed batch with five different oil mixes (vacuum coater, Dinnisen BV, Sevenum, the Netherlands) to give the same total fat content of all diet groups (Table 2).

The oil mix of the different diets contained different levels of VLC-PUFA [0%, 2.5%, 5%, 7.5%, and 10% of total fatty acids, named Control (Ctr), Low-VLC (L-VLC), Intermediate-VLC (I-VLC), Medium-High-VLC (MH-VLC), and High-VLC (H-VLC), respectively], and levels of EPA and DHA were kept constant at 14.9% of the total fatty acids between all the groups. The amount of fish oil was reduced from 18.83% to 10.66% as the amount of VLC-PUFA oil included in the diets increased. Each diet was fed to triplicate tanks. The **total** ingredient composition and PUFA content of the diets are presented in Table 2.

The weights of all the experimental fish in each tank were recorded in bulk at the start of the experiment and after 5 weeks, and growth rates were calculated based on the average weight of the fish in each tank, following the formula described in [27].

### *2.2.1. Fatty acid composition of Atlantic salmon feed*

The fatty acid composition of the experimental salmon diets is presented in Table 3. There was a linear increase in the sum of VLC-PUFAs in the feed, in line with the intended fatty acid composition of the diets. Furthermore, the sum of EPA (20:5 *n*-3) and DHA (22:6 *n*-3) content was approximately the same in all the diet groups. The fatty acid composition of the salmon feed, presented as percentage of total fatty acids, is presented in supplementary Table S1.

### *2.2.2. Fish sampling and sample preparation*

Whole-body samples of 20 fish from each tank were frozen at the start and end of the experiment, including 10 for whole-body lipid composition analyses and 10 for X-ray analyses. At the end of the experiment, 10 fish from each tank were randomly sampled and euthanized by an overdose of the anaesthetic metacain (MS-222; 0.05–0.08 g/L). Samples of vertebrae and skin were frozen in liquid nitrogen (Nippon gases, Norway) and then stored at –80°C for later analysis. Samples of vertebrae were stored in RNAlater (Thermo-Fisher Scientific, Waltham, Massachusetts, USA). The remaining fish in each tank were stripped for faeces, which were frozen at –20°C for later analyses of mineral digestibility.

### *2.2.3. Mineral analysis*

For mineral content analysis, sample preparation followed the method described in [30]. Mineral content analysis was performed on vertebrae and skin. Pooled feed and faeces samples (*n* = 10) from each tank were analysed for minerals together with the inert marker yttrium (Y) in order to measure intestinal mineral uptake, and bioavailability of minerals was determined according to Austreng [31].

#### 2.2.4. Whole-body X-ray and computed tomography (CT) analyses of vertebrae

##### **Skeletal morphology**

The morphology of the vertebral column and skull were examined by means of radiography at the beginning and end ( $n = 5$  per tank) of the experiment. Radiography was performed in a semi-digital system using a mammography X-ray source (IMS Giotto, Pontecchio Marconi, BO, Italy). X-ray images were recorded on coated photoreactive phosphorous (FCR Imaging Plates, Fujifilm, Tokyo, Japan). The image resolution was 20 pixels per  $\text{mm}^2$ , with exposure at 22 kV and 100 mA. Plates were read using an FCR Profect Reader (Fujifilm, Tokyo, Japan). The images were evaluated with respect to any deviation of normal morphology of skeletal structures.

##### **CT**

The bone mineral density (BMD) measurements were done with a Skyscan 1275 micro-CT scanner (CS). The samples and phantoms were scanned with an aluminium filter and a source voltage and current at 50 kV and 200  $\mu\text{A}$ , and a pixel size of 10  $\mu\text{m}$ . The scans were reconstructed with nrecon-reconstruction-software (nrecon, version 1.7.3), with a beam hardening correction of 55 and the min value of the CS to image conversion 0,0000-0,08000. The BMD were found with CT-analyser (CTan, v 1.20.3.0). The scans of the phantoms (0.25  $\text{g}/\text{cm}^3$  and 0.75  $\text{g}/\text{cm}^3$ ) were used for calibration. The BMD in the samples were found by selecting which part of the scans are bones and finding the average BMD in CTan.

#### **2.3. In vitro culture of human foetal osteoblast cells**

An *in vitro* cell culture study using a human foetal osteoblast cell line (hFOB 1.19, ATCC, CRL-11372<sup>TM</sup>) [32] was used to examine the effect of different VLC-PUFA concentrations on expression of proliferation and differentiation-related markers.

Cells were cultured according to the manufacturer's instructions. Basal medium comprised a 1:1 mixture of Ham's F12 Medium Dulbecco's Modified Eagle's Medium with 2.5 mM L-glutamine (without phenol red) (Sigma-Aldrich, Darmstadt, Germany). Complete growth medium was prepared using 0.3 mg/mL G418 (Sigma-Aldrich, Darmstadt, Germany) supplemented with 10% foetal bovine serum (T7524, Sigma-Aldrich, Darmstadt, Germany). Cells were incubated at 34 °C, with 5%  $\text{CO}_2$  (In-Vitro Cell NU-8600E, NUAIRE, Minnesota, U.S.) and subcultured at approximately 80% confluency at a ratio of 1:4. Growth medium was renewed every 2–3 d. Cells cultured for differentiation were supplemented with



osteogenic factors, ascorbic acid (100 µg/mL; A8960, Sigma-Aldrich, Darmstadt, Germany), and β-glycerophosphate (10 mM; G9422, Sigma-Aldrich, Darmstadt, Germany). Once the cells reached confluency, the temperature was increased to 37 °C to stop proliferation and induce differentiation. The osteogenic media was renewed every 2–3 d.

Fatty acids were added to the growth media in the form of their sodium salts bound to bovine serum albumin (BSA, Sigma-Aldrich, Darmstadt, Germany; 2.7:1 molar ratio) as previously described by Bou et al. [33]. The pH was adjusted to 7 using NH<sub>4</sub>OH. *n*-3 VLC-PUFA and DHA (Sigma-Aldrich, Darmstadt, Germany) concentrates were prepared as 1 and 8-mM stocks, respectively, and were added to the media at concentrations of 1 and 2 µM. All fatty acid solutions were stored at –80 °C.

For gene expression analysis of cell proliferation markers, cells were plated in 6-well plates (Thermo-Fisher Scientific, Waltham, Massachusetts, USA) at passage 4–5 at a ratio of 1:3. Growth media was renewed and test substrates were added after an attachment period of 24 h. At days 2 and 3 after plating, cells were harvested for gene expression analysis. The experiment was repeated three times, with three replicates per test dose in all batches except one in which the control group had six replicates. For gene expression analysis of markers related to osteogenic differentiation, the same plating and ratio used for proliferation was used. At day 10 after inducing differentiation, the cells were supplemented with test substrates. Osteogenic growth media with and without the respective test substrates were renewed every 2 to 3 d. At day 7 after adding test substrates, cells were harvested for gene expression analysis, and growth media was frozen and stored at –80 °C for later analysis. The experiment was repeated using three separately thawed cell batches, with six replicates per test dose in one of the experiments, five replicates in the control group, four in the 1 µM and 2 µM VLC-PUFA groups, three in the 1 µM DHA group, and two in the 2 µM DHA group in another experiment, and 11 replicates in the control group and four in each of the remaining groups in the last experiment. The separate experiments were used as an experimental unit ( $n = 3$ ), and as there were no significant differences between the two doses within the VLC-PUFA and DHA groups, the results from the 1 and 2 µM doses were combined.

For fatty acid composition analysis, cells were plated at a ratio of 1:3 from the previous passage (passage 5) in T25 tissue culture flasks (Thermo-Fisher Scientific, Waltham, Massachusetts, USA). Osteogenic differentiation was induced, substrates were added as



previously described, and cells were harvested for fatty acid composition on day 7 after adding the test substrates. Cells were washed twice in phosphate-buffered saline (PBS) with 1% BSA, then twice in PBS, and loosened in 0.5 mL of PBS by using a rubber scraper then transferred into an Eppendorf tube and centrifuged for  $550 \times g$  for 5 min. The PBS was then removed, leaving only the cell pellet in the tube, which was then frozen and stored at  $-80^\circ\text{C}$  until further analysis.

## 2.4. RNA purification and gene expression analysis

### 2.4.1. RNA isolation and cDNA synthesis

Cells were harvested for RNA extraction by washing twice in PBS, then 1 mL of QIAzol™ Lysis Reagent (Qiagen, Valencia, CA, USA) was added to the wells. Cells were then loosened using a rubber scraper and then transferred to a spin column and frozen at  $-80^\circ\text{C}$ . Total RNA was isolated by adding 0.2 mL of chloroform (Merck, Germany) to the samples, vortexing for 15 s, and incubating for 2–3 min. The samples were then centrifuged at  $12,000 \times g$  at  $4^\circ\text{C}$  for 15 min. The aqueous phase was transferred to a new tube and one volume of 95%–100% ethanol was added. RNA was then cleaned using an RNA Clean & Concentrator™-5 kit (Zymo Research, Irvine, CA, USA) according to the manufacturer's protocol. All samples were treated with DNase I (Invitrogen, Carlsbad, USA). The concentration and purity of RNA were evaluated using a NanoDrop 1000 Spectrophotometer (NanoDrop Technologies, USA). cDNA was synthesised using TaqMan reverse transcriptase reagents (Applied Biosystems, Foster, City, CA, USA) according to the manufacturer's protocol.

### 2.4.2. qPCR

The expression of target genes was analysed using a QuantStudio Real-Time PCR analyser (Thermo Fisher Scientific, MA, USA) using two different assays. The proliferation genes *MKI67*, *MYBL2*, *CCNB1*, and *PCNA* were analysed using PowerUp SYBR Green Master Mix (Applied Biosystems, Foster City, California, United States) (Table 4), whereas *RUNX2*, *ALP*, *BGLAP*, and *COL1A1* were analysed using commercially available TaqMan probes (Table 5). The specificity of the primers for the proliferation genes were confirmed by Sanger sequencing (Eurofins Genomics). The qPCR reaction mixture for the TaqMan probe assays consisted of 4  $\mu\text{L}$  of a 1:10 dilution of cDNA, 0.5  $\mu\text{L}$  of primer (Table 5), 0.5  $\mu\text{L}$  of distilled H<sub>2</sub>O, and 5  $\mu\text{L}$  of TaqMan Master Mix (TaqMan™ Gene expression Master Mix, Applied

Biosystems™ 4369514), while the SYBR Green mix contained 4 µL of a 1:10 dilution of cDNA, 1 µL of forward and reverse primers (final concentration of 0.5 µM; Table 4), and 5 µL of PowerUp SYBR Green Master Mix (Applied Biosystems, Foster City, California, United States). All samples were analysed in parallel and non-template and non-enzyme controls were included. The TaqMan-based assays were performed under the following conditions: one cycle at 50 °C for 2 min; amplification for 40 cycles at 95 °C for 15 s; and 60 °C for 1 min. The other assays were performed as follows: one cycle at 50 °C for 2 min followed by 95 °C for 20 s; amplification for 40 cycles at 95 °C for 1 s followed by 60 °C for 20 s; melting at 95 °C for 1 s and 60 °C for 20 s; dissociation at 95 °C for 1 s. RefFinder [34] was used to evaluate the stability of the reference genes (*GAPDH*, *RPOL2*, *EF1A*, and *B2M*). The relative gene expression level was calculated using the  $\Delta\Delta C_t$  method [35] using *GAPDH* as the reference gene for the proliferation genes and *B2M* as the reference gene for the genes related to differentiation (TaqMan probes).

#### 2.4.3. Microarray

Transcriptome analyses of vertebrae (six samples per group) were performed using 15 k Atlantic salmon DNA microarray SIQ-6 ([GPL30031](#)). RNA was extracted using a Biomek 4000 robot using Agencourt RNAdvance Tissue kit (Beckman Coulter), and the quality was assessed using an Agilent Bioanalyzer 2100, RNA 6000 nano kit (RIN > 8). Microarrays, reagents, and equipment were manufactured by Agilent Technologies. RNA amplification and labelling were performed using the One-Color Quick Amp Labelling Kit, and the Gene Expression Hybridization kit was used for fragmentation of labelled RNA. After overnight hybridization (17 h, 65 °C, rotation speed of 0.01 g), the arrays were washed with Gene Expression Wash Buffers 1 and 2 and scanned using an Agilent scanner. Global normalization was performed by equalizing the mean intensities of all microarrays. The individual values for each feature were divided to the mean value of all samples to produce expression ratios (ERs). The log<sub>2</sub>-ER values were normalized with the locally weighted non-linear regression (Lowess). The difference from 0 to control was assessed by criteria: ER >1.75-fold and P < 0.05.

#### 2.5. Fatty acid composition analysis

The method for analyses of total fatty acid composition, except VLC-PUFA, follows the same protocol as described in [20]. Briefly, total lipids were extracted using the Folch method [36], and fatty acid methyl esters were prepared through trans-methylation with 2',2'-

dimethoxypropane, methanolic HCl, and benzene. Gas chromatography (GC) was utilized for the separation and analysis of methyl esters, employing an SGE BPX70 capillary column and a flame ionization detector according to the method described by Lutfi et al., 2023 [37].

For the VLC-PUFA, the same protocol for lipid extraction and methylation was used as explained above, but for VLC-PUFA in feeds and tissues, separate methods were used. For the VLC-PUFA-composition analysis of the diets, the protocol described in [27] was employed, while for the VLC-PUFA composition of cells and whole-body extracts, a Scion TQ 8300 GC-MS/MS with a split/splitless injector (splitless 1 min) with a Restek Rxi-5ms capillary column (length, 30 m; internal diameter, 0.25 mm; and film thickness, 0.25  $\mu\text{m}$ ) was used. Hydrogen was used as the carrier gas, with split-injection and detector temperatures of 250 °C and 270 °C, respectively. The oven temperature started at 90 °C for 1.5 min and was ramped up to 220 °C at a rate of 30 °C/min, then 275 °C at a rate of 1.21 °C/min, and finally 310 °C at a rate of 6.5 °C/min. The instrument was run in multiple reaction monitoring (MRM) mode with 7.1-77.1  $m/z$  and 79-55.1  $m/z$  as transitions for VLC-PUFAs and 143.1-55.1  $m/z$  for C23:0 [38]. The response factor for DHA (relative to C23:0) was calculated using standard solutions of known concentrations of DHA and C23:0. As no standards for VLC fatty acids were available for the VLC-PUFAs, the same response factor as for DHA was assumed and used to calculate concentrations of VLC-PUFAs.

## 2.6. Cytokine quantitation

Cell culture medium from cells harvested for osteogenic differentiation markers was collected for cytokine analysis. Cytokine levels were measured using a Bio-Plex Pro™ Human Cytokine 8-plex assay (#171B5018M, Bio-Rad, Hercules, CA, USA) according to the manufacturer's protocol.

## 2.7. Statistical analysis

The assignment of feeds to each tank was randomized, and no animals were excluded from the study. All fish were included in the analysis. The tanks were coded, and their identities unknown prior to data handling. Similarly, the cell culture experiments were conducted in a blinded manner until the data processing was completed. We employed one-way ANOVA to compare differences among the treatment groups. Significant differences ( $P < 0.05$ ) were further analyzed using Tukey's honest significant difference (HSD) test for group ranking.

Linear regression was applied where appropriate, to explore potential linear relationships between increasing levels of VLC-PUFA and the response variables. Statistical analyses were performed using JMP Pro (SAS Institute Inc., 1989-2019) and Microsoft Office Excel software. GraphPad Prism 9.3.9 was utilized for figure generation.

## **2.8. Ethical approval**

The feeding trial involving Atlantic salmon adhered to Norwegian national regulations governing the use of experimental animals (NARA, FOR-2015-06-751). As per §2-4, corresponding to Directive 2010/53/EU Article 1, section 431 5f, a specific license was not required since the experimental treatments were not anticipated to cause any distress or discomfort to the fish.

## **3. Results**

### **3.1. Atlantic salmon n-3 VLC-PUFA feeding trial**

#### *3.1.1. Growth analysis*

The mean body weights (BW) of the fish at the start and end of the trial, along with the SGR and TGC, are presented in Table 6. The BW of the fish increased threefold during the trial, from a mean start weight of 5.7 g to a mean final weight of 17 g. There were no significant differences in final BW ( $P = 0.28$ ), SGR ( $P = 0.55$ ), or TGC (and  $P = 0.55$ ) between the different diet groups. There were no observed mortalities in any of the dietary groups.

There were no significant differences in bioavailability of the minerals P or Mg between the different diet groups (Table 7). However, Zn showed a significant difference between the groups, with a moderately lower bioavailability in the I-VLC and H-VLC diet groups compared with the control group ( $P = 0.01$ ).

#### *3.1.2. Whole-body fatty acid composition of Atlantic salmon*

Analysis of whole-body fatty acid composition showed there were no significant differences in the amount of fatty acids containing  $\leq 22$  carbon atoms between the different dietary groups (Table 8). The aim of obtaining the same whole-body content of EPA and DHA in all dietary groups was achieved, with a body content of 14 mg/g of these fatty acids.

The VLC-PUFA composition of whole-body homogenate showed a significant increase in VLC-PUFAs from the diet, with the highest amount in the High-VLC diet group (Table 9,

Figure 1). The 24:6 *n*-3 content increased from 1.07 mg/g tissue in the Low-VLC diet group to 2.31 mg/g tissue in the High-VLC diet group ( $P < 0.0001$ ), and 24:5 *n*-3 increased from 0.86 mg/g tissue in the Low-VLC diet group to 1.82 mg/g tissue in the High-VLC diet group ( $P = 0.0004$ ). While 26:7 *n*-3 and 26:5 *n*-3 were both undetected in the Low-VLC diet group, they were detected at levels of 0.03 mg/g tissue and 0.24 mg/g tissue, respectively, in the High-VLC diet group ( $P < 0.0001$ ). Furthermore, 26:6 *n*-3 increased from 0.03 mg/g tissue in the Low-VLC diet group to 0.88 mg/g tissue in the High-VLC diet group ( $P < 0.0001$ ), and 28:8 *n*-3 increased from 0.02 mg/g tissue in the Low-VLC diet group to 2.40 mg/g tissue in the High-VLC diet group ( $P < 0.0001$ ).

### *3.1.3. Skeletal morphology and mineral component analysis of skin and vertebrae*

The results of the mineral component analysis of salmon skin and vertebrae are presented in Tables 9 and 10, respectively. In the skin from Atlantic salmon fed increasing dietary levels of VLC-PUFAs, P increased by ~28% in the High VLC-PUFA group compared with the control group, and Ca and Mg increased by ~32% ( $P = 0.01$ ) and ~19% ( $P = 0.02$ ), respectively.

In the vertebrae from Atlantic salmon fed increasing dietary levels of VLC-PUFAs, P increased by 22% from the control group to the High VLC-PUFA group ( $P = 0.02$ ). Ca and Mg also increased with increasing levels of VLC-PUFAs in the feed; Ca increased by ~25% ( $P = 0.02$ ) and Mg increased by around 14% ( $P = 0.01$ ).

### **Radiography of Atlantic salmon vertebrae**

X-ray analyses of the fish in the different diet groups showed no significant differences in pathology, and the skeletal structures appeared uniform and well developed. Hyper-dense (HD) vertebrae [39] were observed in five of the 75 fish examined; however, these were randomly distributed between the diet groups (Figure 2). The HD lesions were similar in all affected individuals and consisted of one to three vertebrae with increased radiodensity compared with the adjacent structures. The lesions were localized to the cranium and under the dorsal fin.

## CT analyses

CT analyses of fish from the different diet groups revealed a significantly higher BMD in the H-VLC-diet group compared with the other diet groups, with the lowest levels observed in the control group (Figure 3).

### 3.1.4. Microarray analysis results

The dietary effects on gene expression in bone were small, with two to 10 differentially expressed genes (DEGs) identified. Only two genes showed differences in more than one group. Several DEGs may be associated with bone-related processes (Figure 4). *B-cell lymphoma 6a (Bcl6)* was downregulated twofold in the High-VLC diet group, and *coagulation factor IX* was also downregulated in the same group. *Galectin-9* showed reduced expression in the Medium-High-VLC diet group, while *isg15* was significantly downregulated in three dietary groups. *Mmp2 inhibitor* showed the highest expression in the Low-VLC diet group, and *collagenase 3 (mmp13)* showed significant upregulation in both the Low-VLC and High-VLC diet groups. *Osteocalcin* was downregulated in the Low-VLC diet group, and the same was *procollagen-lysine dioxygenase 2*. Finally, *retinol binding protein 4* was downregulated in the Medium-High-VLC diet group.

## 3.2. In vitro cell culture of hFOB 1.19 human foetal osteoblasts

### 3.2.1. Fatty acid composition of human foetal osteoblasts

The cell culture media were supplemented with 2  $\mu$ M VLC-PUFA, and a 2  $\mu$ M DHA group was included as positive control, as well as a control group without any supplementation. The fatty acid composition of the cells after 7 days of supplementation is presented in Table 11. Levels of EPA (20:5 *n*-3) were significantly different between the three groups, with a slightly higher level in the 2  $\mu$ M VLC-PUFA group, although the supplemented VLC-PUFA concentrate did not contain this fatty acid ( $P = 0.0232$ ). DHA (22:6 *n*-3) was also significantly different between the groups, with the highest level observed in the 2  $\mu$ M DHA group ( $P = 0.0013$ ), likely due to the VLC-PUFA concentrate containing this fatty acid. There was also a significant difference in the sum of *n*-3 PUFAs, with the highest level in the 2  $\mu$ M VLC-PUFA group ( $P = 0.0248$ ). Levels of the VLC-PUFA 26:6 *n*-3 were significantly higher in the group supplemented with VLC-PUFA concentrate (2  $\mu$ M) compared with the control and DHA groups ( $P = 0.0389$ ). The same was true also for 26:5 *n*-3 ( $P = 0.304$ ) and 28:8 *n*-3 ( $P = 0.0022$ ).

### 3.2.2. *qPCR*

The different diet groups showed no significant differences in the expression of the proliferation markers: marker of proliferation Ki-67 (*MKI67*), MYB proto-oncogene like 2 (*MYBL2*), cyclin B1 (*CCNB1*), and proliferating cell nuclear antigen (*PCNA*). However, there was a trend towards higher expression of *PCNA* in the control group on day 2, which was reversed on day 3, with a trend towards higher expression in the 1  $\mu$ M VLC-PUFA group and 2  $\mu$ M DHA group, albeit not significant (data presented in Supplementary Figure S1).

As there were no significant differences between the two different test doses of the supplemented fatty acids, the combined effect of 1 and 2  $\mu$ M VLC-PUFA as well as 1 and 2  $\mu$ M DHA are presented for the cells cultured for analysis of the differentiation markers: runt-related transcription factor 2 (*RUNX2*), alkaline phosphatase (*ALP*), bone gamma-carboxyglutamate protein (*BGLAP*), and collagen type I alpha 1 chain (*COL1A1*) (Figure 5). There were significantly higher levels of *BGLAP* and *COL1A1* in both the DHA and VLC-PUFA groups compared with the control group in experiment 1 (Figure 5A). However, when combining the means of all three experiments, there were no significant differences, although there was a slight trend of increased levels of *BGLAP* and *COL1A1* in the DHA and VLC-PUFA supplemented groups (Figure 5D).

### 3.2.3. *Cytokine quantitation*

Cytokine quantitation of growth medium from hFOB 1.19 cells cultured for gene expression analysis of differentiation markers revealed significant differences in the expression of TNF- $\alpha$ , IL-4, IL-2, IFN- $\gamma$ , and GM-CSF, with lower expression in the 2  $\mu$ M VLC-PUFA group. Expression of GM-CSF was significantly higher in the 1  $\mu$ M VLC-PUFA group, while it was lowest in the 2  $\mu$ M VLC-PUFA group (Figure 6). Although not statistically significant, there was a slight trend towards lower expression of IL-8 in the two VLC-PUFA and 2  $\mu$ M DHA groups compared with the control.

## 4. Discussion

The present study investigated the impact of dietary *n*-3 VLC-PUFAs on skin and bone mineral composition, BMD, and gene expression profiles within the skeletal systems of Atlantic salmon. The choice of Atlantic salmon as an *in vivo* model was based on several considerations, in particular the fact that several major physiological and morphological



features are shared between teleost and mammalian bones [21]. The physiological and genetic proximity of fish, in this case, Atlantic salmon, to humans allows for insightful extrapolation of findings relevant to our own species [40], and the feasibility of controlled dietary interventions and their relatively rapid growth facilitates a comprehensive assessment of the dietary impact during the developmental period [41, 42]. To bridge the gap between animal models and the potential relevance for human skeletal health, we also investigated the effects on human foetal osteoblasts *in vitro* to elucidate the translational relevance of our findings.

The Atlantic salmon feeding trial demonstrated a substantial threefold increase in BW of the fish, indicating successful growth during the experimental period. The SGR and TGC values among the different dietary groups showed that supplementation of VLC-PUFAs did not exert significant effects on the overall growth performance of the fish, and X-ray analysis also showed no notable effects on the skeletal morphology. However, the fish in all the dietary groups had vertebrae mineral contents within the considered normal range [43], which is expected since all the fish were fed minerals according to their requirements. This likely explains why no major pathologies or deviations from normal morphology of vertebrae were recorded with X-ray analyses. The good growth and survival (100%) of the experimental fish fed increasing dietary levels of VLC-PUFAs confirmed that there were no major fish health concerns regarding this ingredient. These results align with our previous studies, albeit with variations in VLC-PUFA composition and dietary concentrations [20, 27], and are consistent with findings demonstrating the safety of VLCFAs [44]. The whole-body fatty acid composition of the salmon revealed a linear increase in several VLC-PUFAs, including 24:6 *n*-3, 24:5 *n*-3, 26:7 *n*-3, 26:5 *n*-3, 26:6 *n*-3, and 28:8 *n*-3. There were no significant differences in EPA and DHA, in accordance with the content of these fatty acids in the diet. These findings demonstrate the successful deposition of VLC-PUFAs in fish through dietary supplementation, as also previously shown [20, 27]. Other studies have demonstrated that VLC-PUFAs are present in sphingolipids in skin and sperm [45], and predominantly in total phospholipids in neuronal tissue and the brain [46, 47]. While we have previously shown in [27] that VLC-PUFAs are also incorporated into triglycerides which the bone marrow is very rich in [48]. In our study, we focused on total lipids including all polar and unpolar lipids in the whole body, as it remains unknown which lipid classes are most important for VLC-PUFAs in tissues such as bone. This will be an important area for further investigation.

A significant correlation between increased dietary *n*-3 VLC-PUFAs and elevated P, Ca, and Mg content within both the skin and vertebrae were also found, as well as increased BMD of salmon vertebrae. Similar findings were shown in a study where the effects of long-term dietary fish oil supplementation on bone health were investigated [49]. This study demonstrated that fish oil supplementation significantly increased tibial mineral content, mechanical properties, and histological parameters compared with other dietary fats in Japanese quail [49]. As the sum of EPA and DHA levels were kept constant between all dietary groups in our study, our findings suggest an independent effect of the VLC-PUFA concentrate. However, it is important to address whether the observed differences were a direct consequence of VLC-PUFA intake or whether other factors, such as altered mineral absorption across the intestinal barrier, could contribute to the higher levels. Additionally, while our study focused on P, Ca, and Mg, consideration of other trace minerals like copper, manganese, and selenium, which also contribute to bone mineralization, could provide valuable insights in future research.

To investigate the possible role of intestinal absorption in the elevated mineral content, we assessed the intestinal bioavailability of the dietary minerals P, Mg, and Zn across the different dietary groups. No differences in the intestinal bioavailability of P and Mg between the dietary groups suggest that the increased mineral content in the skin and vertebrae are attributed to other functions than intestinal mineral absorption. The only mineral that showed significant differences was Zn, which was lower in the VLC-PUFA-supplemented groups. This was however not reflected in the vertebrae and skin samples, indicating that the elevated mineral levels observed in the tissues are unlikely to be driven by differences in intestinal uptake alone. This is an interesting finding, as prior studies have shown the potential of *n*-3 LC-PUFA supplementation to enhance bone calcium content through increased intestinal absorption and decreased urinary excretion [50]. P and Ca are known to be the most relevant nutrients to bone health, as they comprise around 80%–90% of the mineral content of bone hydroxyapatite [51], while Mg depletion has been shown to have a profound effect on bone, characterized by impaired bone growth, reduced osteoblast number, and increased osteoclast number [52]. Previous studies have also demonstrated that increasing dietary levels of fish oil in Atlantic salmon feed improves the mineral content of the fish [53]. Our observed correlation between *n*-3 VLC-PUFAs and mineral content further underscores the possibility that VLC-PUFAs could play a pivotal role in shaping the mineral composition of fish tissues, potentially influencing overall skeletal health. While vitamin D in fish oil is known to

contribute to calcium absorption and bone health [54], the natural vitamin D content in the raw fish oil is largely depleted during the refining process [55]. Therefore, our VLC-PUFA concentrate likely contains minimal levels of vitamin D, suggesting that its influence on the observed effects is minimal, and making VLC-PUFAs key factors in these outcomes.

Our study, as well as evidence from both human and animal studies, highlights the intricate link between dietary lipids and bone metabolism [50]. Notably, *n*-3 fatty acids have garnered considerable attention due to their impact on enhancing BMD [56-58] and positive influence on bone metabolism [50, 59]. Recent studies have identified strong association between gene variants of ELOVL with bone density, with evidence linking these variants to the incidence of fractures [60]. Furthermore, microRNA regulation of ELOVL4 has been shown to be implicated in fracture susceptibility, as demonstrated by Dai et al. [61]. Additionally, a study by Arsic et al. [62] have shown that reduced PUFA levels in plasma may influence hip fracture repair and contribute to femoral fracture susceptibility in the elderly, underscoring the potential benefit of PUFA intervention in both fracture prevention and healing. In our study, analysing gene expression in the vertebrae revealed subtle yet significant impacts on bone-related processes. Although the number of DEGs was relatively modest, their potential implications for bone health are noteworthy. In particular, the observed twofold downregulation of *B-cell lymphoma (Bcl6)* in the High-VLC diet group underscores the potential influence of *n*-3 VLC-PUFAs on regulatory pathways in bone, since *Bcl6* is recognized for its pivotal role in orchestrating osteoblast activation and inhibition [63, 64]. *Coagulation factor IX*, which is known to be essential for proper skeletal development [65], was downregulated in the vertebrae of the High-VLC diet group. Furthermore, *galectin-9*, which is implicated in osteoblast differentiation [66], displayed reduced expression in the Medium-High-VLC diet group. These regulations point to potential intricacies in the interaction between dietary factors and molecular mechanisms governing bone cell differentiation. Conversely, *mmp2 inhibitor*, which is associated with enhanced bone formation and prevention of bone loss [67], exhibited the highest expression in the Low-VLC diet group. Additionally, *collagenase 3 (mmp13)*, which is critical for restructuring the collagen matrix during bone mineralization, showed significant upregulation in both the Low-VLC and High-VLC diet groups. This dynamic expression pattern further hints at complex regulatory mechanisms influenced by dietary factors. Notably, some genes critical for bone formation showed contradictory expression patterns. *Osteocalcin*, an essential factor for bone formation [68], and *procollagen-lysine dioxygenase 2*, which plays a role in forming robust

collagen fibres [69], were downregulated in the Low-VLC diet group and the higher VLC-PUFA diet groups were not significantly affected. Moreover, *retinol binding protein 4*, linked to bone mineral density in conditions such as type 2 diabetes and osteoporosis [70], emerged as a downregulated gene in the Medium-High-VLC diet group.

Genotoxicity studies have established that VLC-FAs do not exhibit genotoxic potential at doses up to 1200 mg/kg body weight per day (using a fish oil concentrate where VLC-PUFAs accounted for 10% of the fatty acids), as reported in Sprague Dawley rats over a 90-day feeding period [71]. In our study on Atlantic salmon, the fish were administered feeding containing various concentrations of VLC-PUFA concentrate, with the highest doses being 1.9% VLC-PUFA concentrate per 100 g of feed. The fish consumed an estimated amount of VLC-PUFA concentrate that equates to 380 mg/kg body weight per day. This intake level is well below the established NOAEL of 1200 mg/kg body weight per day, which is consistent with the no adverse effects observed in the fish in our trial. Nevertheless, the highest dosage provided in our study, which equates to 380 mg/kg body weight per day, demonstrated a significant increase in BMD, which may represent a relevant safe dietary dose also for humans based on the rat toxicity trial. This suggests a potential positive biological response that may be relevant for further exploration in human studies.

In contrast to our *in vivo* study, where we balanced EPA and DHA levels in the tissues to isolate the effects of VLC-PUFAs, the aim of our *in vitro* study was to directly compare the effects of VLC-PUFAs against those of DHA. By doing so, we seek to clarify the distinct roles and potential advantages of VLC-PUFAs in cellular processes, relative to DHA, within a controlled environment. Our *in vitro* studies with human foetal osteoblast cells supplemented with VLC-PUFAs or DHA identified trends in the expression of key markers associated with bone development and maturation, namely *BGLAP* and *COL1A1* [72], in both the DHA and VLC-PUFA groups compared with the control. Although not statistically significant, these trends aligned with *in vivo* findings, suggesting the possibility of DHA and VLC-PUFAs influencing the expression of key markers associated with bone development and maturation. However, further investigations are needed to explore the underlying mechanisms and confirm these trends. As several inflammatory cytokines are known to be involved in bone metabolism [73], we also analysed cytokine expression in the growth medium from the human foetal osteoblast cells analysed for expression of bone differentiation markers. There was slightly lower level of IL-8 in the VLC-PUFA-

supplemented groups and slightly lower level of IL-6 in the 2  $\mu$ M VLC-PUFA group. Additionally, TNF- $\alpha$ , IL-4, IFN- $\gamma$ , and GM-CSF were significantly lower in the 2  $\mu$ M VLC-PUFA group compared to control. These trends could indicate a subtle modulation of cytokine responses due to VLC-PUFA supplementation. As TNF- $\alpha$  is known to play a dual role in bone remodelling through stimulation of osteoclastogenesis and inhibition of osteoblast function [74], reduced levels of TNF- $\alpha$  can help maintain a balance between bone resorption and formation. Furthermore, IL-4 and IFN- $\gamma$  have inhibitory effects on bone resorption [75], and reduced levels may thus also contribute to maintaining a balance between bone resorption and formation.

The impacts of *n*-3 VLC-PUFAs on bone formation were studied in both Atlantic salmon and a human cell line. While notable effects were observed in both cases, the differences between the two methods preclude direct comparison. For one, we acknowledge that the dietary oil used in the fish model contained a mix of VLC-PUFAs and shorter chain fatty acids including EPA and DHA, while a more pure VLC-PUFA concentrate was used in the human cell model. These differences may affect the interpretation of the functions of VLC-PUFAs between the two models. For instance, it is previously shown that EPA and DHA from diet may to a moderate degree be further converted to certain VLC-PUFAs [27]. It is therefore essential to acknowledge the potential variations between an *in vivo* fish model and a human *in vitro* cell model, both in their response to dietary fatty acids, as well as their physiological differences. The observed similarities between *in vivo* findings from fish and *in vitro* findings from human cells are still interesting pointing to the possible important roles of VLC-PUFAs in bone development in vertebrates across different species.

## 5. Conclusions

Our study provides initial evidence that dietary supplementation with *n*-3 VLC-PUFAs may increase the mineral content of the skin and vertebrae of Atlantic salmon and affect the expression of several genes involved in bone-related processes. CT analyses further demonstrated a significant increase in BMD with increasing *n*-3 VLC-PUFAs in the diet, consistent with the findings of increased mineral content of the vertebrae. The human foetal osteoblast experiments showed trends towards increased expression of the genes *BGLAP* and *COL1A1* which are known to have important functions during bone development. The

presented study provides novel insight into the intricate relationship between dietary *n*-3 VLC-PUFAs, bone and skin mineral content, which to our knowledge, has not previously been explored. Overall, our study contributes valuable insight into the potential role of *n*-3 VLC-PUFAs in bone health. Further studies into the underlying molecular mechanisms are needed to elucidate the complex relationship between nutrition and bone physiology, particularly in relation to *n*-3 VLC-PUFAs, and to conclude if VLC-PUFAs have different functions in fish and mammals.

### **Acknowledgments**

The authors especially wish to thank Anne Marie Langseter for all her work related to the lipid analyses, Vibeke Voldvik, Marianne Vaadal and Marianne H.S. Hansen for their assistance in the laboratory, Grete Baeverfjord for her contributions with the X-ray analysis and interpretation of the data, and Iren Stoknes for her support throughout the work of this project.

### **Financial support**

This work was part of two projects funded by The Research Council of Norway: NRC no. 310 433 and NRC no. 321 447.

### **Conflicts of Interest**

The first author (M.T.) has a PhD position, which is partly funded by an Innovation project in the Norwegian Research Council (project no. 310 433) and by the industry partner Epax Norway AS (Aalesund, Norway). Epax Norway has patents and patent applications related to VLC-PUFA. However, since this project has public funding, all results are open and there is no conflict of interest in publishing all findings in an open-access journal.

**Data Availability Statement:** The raw data behind the results presented in this study are available upon request to the corresponding author.

### **Author Contributions**

Conceptualization, E.Y. and B.R.; methodology, H.S., M.T., E.Y., T-K.Ø.; software, M.T., G.B. and A.K.; validation, M.T., B.R.; formal analysis, M.T., G.B., T-K.Ø. and A.K.; investigation, M.T., E.Y. and B.R.; data curation, M.T., G.B., A.K. and B.R.; writing—original draft preparation, M.T., E.Y. and B.R.; writing—review and editing, M.T., E.Y.,

B.R., S.R.; visualization, M.T., A.K.; supervision, B.R.; project administration, B.R.; funding acquisition, B.R. All authors have read and agreed to the published version of the manuscript.

## References

1. Barnsley, J., et al., *Pathophysiology and treatment of osteoporosis: challenges for clinical practice in older people*. Aging clinical and experimental research, 2021. **33**: p. 759-773.
2. Zhang, C. and C. Song, *Combination therapy of PTH and antiresorptive drugs on osteoporosis: a review of treatment alternatives*. Frontiers in Pharmacology, 2021. **11**: p. 607017.
3. Brar, K., *Prevalent and emerging therapies for osteoporosis*. Medical Journal Armed Forces India, 2010. **66**(3): p. 249-254.
4. Skjødt, M.K., M. Frost, and B. Abrahamsen, *Side effects of drugs for osteoporosis and metastatic bone disease*. British journal of clinical pharmacology, 2019. **85**(6): p. 1063-1071.
5. Banu, J. and G. Fernandes, *Fish Oil with Higher DHA Content and Voluntary Exercise Decreases Postmenopausal Bone Loss*. Journal of Osteoporosis & Physical Activity, 2017.
6. Fernandes, G., R. Lawrence, and D. Sun, *Protective role of n-3 lipids and soy protein in osteoporosis*. Prostaglandins, leukotrienes and essential fatty acids, 2003. **68**(6): p. 361-372.
7. Sun, D., et al., *Dietary n-3 fatty acids decrease osteoclastogenesis and loss of bone mass in ovariectomized mice*. Journal of Bone and Mineral Research, 2003. **18**(7): p. 1206-1216.
8. Fernandes, G., et al., *Effects of n-3 fatty acids on autoimmunity and osteoporosis*. Front Biosci, 2008.
9. Chen, Y.-M., S. Ho, and S. Lam, *Higher sea fish intake is associated with greater bone mass and lower osteoporosis risk in postmenopausal Chinese women*. Osteoporosis international, 2010. **21**(6): p. 939-946.



10. Lage, S., et al., *Fatty acid profile in patients with phenylketonuria and its relationship with bone mineral density*. Journal of Inherited Metabolic Disease: Official Journal of the Society for the Study of Inborn Errors of Metabolism, 2010. **33**: p. 363-371.
11. Pino, A.M. and J.P. Rodríguez, *Is fatty acid composition of human bone marrow significant to bone health?* Bone, 2019. **118**: p. 53-61.
12. Sharma, T. and C.C. Mandal, *Omega-3 fatty acids in pathological calcification and bone health*. Journal of food biochemistry, 2020. **44**(8): p. e13333.
13. Ytteborg, E., et al., *Atlantic salmon (*Salmo salar*) muscle precursor cells differentiate into osteoblasts in vitro: polyunsaturated fatty acids and hyperthermia influence gene expression and differentiation*. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids, 2010. **1801**(2): p. 127-137.
14. Casado-Díaz, A., et al., *The omega-6 arachidonic fatty acid, but not the omega-3 fatty acids, inhibits osteoblastogenesis and induces adipogenesis of human mesenchymal stem cells: potential implication in osteoporosis*. Osteoporosis International, 2013. **24**(5): p. 1647-1661.
15. Kihara, A., *Very long-chain fatty acids: elongation, physiology and related disorders*. J Biochem, 2012. **152**(5): p. 387-95.
16. Deak, F., et al., *Novel Cellular Functions of Very Long Chain-Fatty Acids: Insight From ELOVL4 Mutations*. Front Cell Neurosci, 2019. **13**: p. 428.
17. Bennett, L.D. and R.E. Anderson, *Current Progress in Deciphering Importance of VLC-PUFA in the Retina*. Adv Exp Med Biol, 2016. **854**: p. 145-51.
18. Agbaga, M.P., *Different Mutations in ELOVL4 Affect Very Long Chain Fatty Acid Biosynthesis to Cause Variable Neurological Disorders in Humans*. Adv Exp Med Biol, 2016. **854**: p. 129-35.
19. Cameron, D.J., et al., *Essential role of Elovl4 in very long chain fatty acid synthesis, skin permeability barrier function, and neonatal survival*. Int J Biol Sci, 2007. **3**(2): p. 111-9.
20. Torrissen, M., et al., *Investigation of the Functions of n-3 Very-Long-Chain Polyunsaturated Fatty Acids in Skin using in vivo Atlantic Salmon and in vitro Human and Fish Skin Models*. British Journal of Nutrition, 2023: p. 1-46.
21. Suzuki, N., K.-i. Kitamura, and A.J.E. Hattori, *Fish scale is a suitable model for analyzing determinants of skeletal fragility in type 2 diabetes*. 2016, Springer. p. 575-577.

22. Suzuki, N., et al., *Effect of vibration on osteoblastic and osteoclastic activities: Analysis of bone metabolism using goldfish scale as a model for bone*. 2007. **40**(11): p. 1711-1721.
23. Fujisawa, R. and M. Tamura, *Acidic bone matrix proteins and their roles in calcification*. *Frontiers in Bioscience-Landmark*, 2012. **17**(5): p. 1891-1903.
24. Long, F., *Building strong bones: molecular regulation of the osteoblast lineage*. *Nature reviews Molecular cell biology*, 2012. **13**(1): p. 27-38.
25. Carmona-Antoñanzas, G., et al., *Biosynthesis of very long-chain fatty acids (C<sup>></sup> 24) in Atlantic salmon: Cloning, functional characterisation, and tissue distribution of an *Elovl4* elongase*. *Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology*, 2011. **159**(2): p. 122-129.
26. Svensen, H. and H. Breivik, *Very long chain polyunsaturated fatty acids from natural oils*. 2016, Epax Norway AS, Ålesund (NO). p. 14.
27. Torrissen, M., et al., *Deposition and metabolism of dietary n-3 very-long-chain PUFA in different organs of rat, mouse and Atlantic salmon*. *Br J Nutr*, 2021: p. 1-20.
28. Bogevik, A.S., et al., *Disintegration stability of extruded fish feed affects gastric functions in Atlantic salmon (*Salmo salar*)*. *Aquaculture*, 2021. **543**: p. 737006.
29. Hatlen, B., et al., *Addition of yttrium oxide as digestibility marker by vacuum coating on finished pellets—A method for assessing digestibility in commercial salmon feeds?* *Aquaculture*, 2015. **435**: p. 301-305.
30. Kokkali, M., et al., *Optimisation of trace mineral supplementation in diets for Atlantic salmon smolt with reference to holistic fish performance in terms of growth, health, welfare, and potential environmental impacts*. *Frontiers in Physiology*, 2023. **14**: p. 1214987.
31. Austreng, E., *Digestibility determination in fish using chromic oxide marking and analysis of contents from different segments of the gastrointestinal tract*. *Aquaculture*, 1978. **13**(3): p. 265-272.
32. Harris, S.A., et al., *Development and characterization of a conditionally immortalized human fetal osteoblastic cell line*. *Journal of Bone and Mineral Research*, 1995. **10**(2): p. 178-186.
33. Bou, M., et al., *EPA, DHA, and Lipoic Acid Differentially Modulate the n-3 Fatty Acid Biosynthetic Pathway in Atlantic Salmon Hepatocytes*. *Lipids*, 2017. **52**(3): p. 265-283.

34. Xie, F., et al., *miRDeepFinder: a miRNA analysis tool for deep sequencing of plant small RNAs*. 2012. **80**(1): p. 75-84.
35. Pfaffl, M.W.J.A.o.q.P., *Quantification strategies in real-time PCR*. 2004. **1**: p. 89-113.
36. Folch, J., M. Lees, and G.H. Sloane Stanley, *A simple method for the isolation and purification of total lipides from animal tissues*. J Biol Chem, 1957. **226**(1): p. 497-509.
37. Lutfi, E., et al., *Increasing dietary levels of the n-3 long-chain PUFA, EPA and DHA, improves the growth, welfare, robustness and fillet quality of Atlantic salmon in sea cages*. British Journal of Nutrition, 2023. **129**(1): p. 10-28.
38. Schött, H.-F., et al., *A validated method for quantification of fatty acids incorporated in human plasma phospholipids by gas chromatography–triple quadrupole mass spectrometry*. ACS omega, 2021. **6**(2): p. 1129-1137.
39. Helland, S., et al., *Hyper dense vertebrae and mineral content in Atlantic salmon (*Salmo salar* L.) fed diets with graded levels of phytic acid*. Aquaculture, 2006. **261**(2): p. 603-614.
40. Ostrander, G., *The laboratory fish*. 2000: Elsevier.
41. Rakers, S., et al., *'Fish matters': the relevance of fish skin biology to investigative dermatology*. 2010. **19**(4): p. 313-324.
42. Adewumi, A., *The impact of nutrition on fish development, growth and health*. International Journal of Scientific and Research Publications, 2018. **8**(6): p. 147-153.
43. Ytteborg, E., et al., *Utilization of acid hydrolysed phosphorous from herring bone by-products in feed for Atlantic salmon (*Salmo salar*) start-feeding fry*. Aquaculture, 2016. **459**: p. 173-184.
44. Tobin, D., et al., *Genotoxicity evaluation of a fish oil concentrate containing Very Long Chain Fatty Acids*. Toxicology Reports, 2023.
45. Sandhoff, R., *Very long chain sphingolipids: tissue expression, function and synthesis*. FEBS letters, 2010. **584**(9): p. 1907-1913.
46. Agbaga, M.-P., M.N.A. Mandal, and R.E. Anderson, *Retinal very long-chain PUFAs: new insights from studies on ELOVL4 protein*. Journal of lipid research, 2010. **51**(7): p. 1624-1642.
47. Siddiqui, A.J., et al., *Therapeutic Role of ELOVL in Neurological Diseases*. ACS omega, 2023. **8**(11): p. 9764-9774.

48. Hardouin, P., V. Pansini, and B. Cortet, *Bone marrow fat*. *Joint Bone Spine*, 2014. **81**(4): p. 313-319.
49. Liu, D., et al., *Long-term supplementation of various dietary lipids alters bone mineral content, mechanical properties and histological characteristics of Japanese quail*. *Poultry Science*, 2003. **82**(5): p. 831-839.
50. Watkins, B.A., et al., *Modulatory effect of omega-3 polyunsaturated fatty acids on osteoblast function and bone metabolism*. *Prostaglandins, leukotrienes and essential fatty acids*, 2003. **68**(6): p. 387-398.
51. Kajarabille, N., et al., *A new insight to bone turnover: role of-3 polyunsaturated fatty acids*. *The Scientific World Journal*, 2013. **2013**.
52. Rude, R., et al., *Magnesium deficiency: effect on bone and mineral metabolism in the mouse*. *Calcified tissue international*, 2003. **72**: p. 32-41.
53. Selvam, C., et al., *Long-term feeding of Atlantic salmon with varying levels of dietary EPA+ DHA alters the mineral status but does not affect the stress responses after mechanical delousing stress*. *British Journal of Nutrition*, 2022. **128**(12): p. 2291-2307.
54. Christakos, S., et al., *Vitamin D and intestinal calcium absorption*. *Molecular and cellular endocrinology*, 2011. **347**(1-2): p. 25-29.
55. Olli, J.J., H. Breivik, and O. Thorstad, *Removal of persistent organic pollutants in fish oils using short-path distillation with a working fluid*. *Chemosphere*, 2013. **92**(3): p. 273-278.
56. Rozner, R., et al., *The role of omega-3 polyunsaturated fatty acids from different sources in bone development*. *Nutrients*, 2020. **12**(11): p. 3494.
57. Lavado-García, J., et al., *Long-chain omega-3 polyunsaturated fatty acid dietary intake is positively associated with bone mineral density in normal and osteopenic Spanish women*. *PloS one*, 2018. **13**(1): p. e0190539.
58. Högström, M., P. Nordström, and A. Nordström, *n- 3 Fatty acids are positively associated with peak bone mineral density and bone accrual in healthy men: the NO2 Study*. *The American journal of clinical nutrition*, 2007. **85**(3): p. 803-807.
59. Maggio, M., et al., *The effect of polyunsaturated fatty acids on bone health*. *Reviews in Clinical Gerontology*, 2011. **21**(3): p. 219-232.
60. Yuan, S., et al., *Plasma phospholipid fatty acids, bone mineral density and fracture risk: Evidence from a Mendelian randomization study*. *Clinical Nutrition*, 2020. **39**(7): p. 2180-2186.

61. Dai, Y., et al., *Differentially expressed microRNAs as diagnostic biomarkers for infected tibial non-union*. *Injury*, 2021. **52**(1): p. 11-18.
62. Arsic, A., et al., *Adverse plasma fatty acid composition in patients with femoral neck fracture I*. *Canadian Journal of Physiology and Pharmacology*, 2020. **98**(2): p. 61-66.
63. Fujie, A., et al., *Bcl6 promotes osteoblastogenesis through Stat1 inhibition*. *Biochemical and biophysical research communications*, 2015. **457**(3): p. 451-456.
64. Miyauchi, Y., et al., *The Blimp1–Bcl6 axis is critical to regulate osteoclast differentiation and bone homeostasis*. *Journal of Experimental Medicine*, 2010. **207**(4): p. 751-762.
65. Larson, E.A., et al., *Deletion of coagulation factor IX compromises bone mass and strength: murine model of hemophilia B (Christmas Disease)*. *Calcified Tissue International*, 2021. **109**(5): p. 577-585.
66. Tanikawa, R., et al., *Galectin-9 induces osteoblast differentiation through the CD44/Smad signaling pathway*. *Biochemical and biophysical research communications*, 2010. **394**(2): p. 317-322.
67. Jiang, L., et al., *The effect of MMP-2 inhibitor 1 on osteogenesis and angiogenesis during bone regeneration*. *Frontiers in Cell and Developmental Biology*, 2021. **8**: p. 596783.
68. Komori, T., *Functions of osteocalcin in bone, pancreas, testis, and muscle*. *International journal of molecular sciences*, 2020. **21**(20): p. 7513.
69. Peltonen, L., R. Halila, and L. Ryhänen, *Enzymes converting procollagens to collagens*. *Journal of cellular biochemistry*, 1985. **28**(1): p. 15-21.
70. Huang, N., et al., *Retinol-binding protein 4 is positively associated with bone mineral density in patients with type 2 diabetes and osteopenia or osteoporosis*. *Clinical Endocrinology*, 2018. **88**(5): p. 659-664.
71. Tobin, D., et al., *Genotoxicity evaluation of a fish oil concentrate containing Very Long Chain Fatty Acids*. *Toxicology Reports*, 2023. **11**: p. 249-258.
72. Huang, W., et al., *Signaling and transcriptional regulation in osteoblast commitment and differentiation*. *Frontiers in bioscience: a journal and virtual library*, 2007. **12**: p. 3068.
73. Beiler, T.F., et al., *Impact of non-surgical periodontal treatment on salivary expression of cytokines related to bone metabolism*. *Odontology*, 2020. **108**: p. 646-652.

74. Osta, B., G. Benedetti, and P. Miossec, *Classical and paradoxical effects of TNF- $\alpha$  on bone homeostasis*. *Frontiers in immunology*, 2014. **5**: p. 48.
75. Kabashima, H., et al., *Presence of IFN- $\gamma$  and IL-4 in human periapical granulation tissues and regeneration tissues*. *Cytokine*, 2001. **14**(5): p. 289-293.




Figure 1. VLC-PUFA composition of whole-body homogenate. Ctr, Control; L-VLC, Low-VLC; I-VLC, Intermediate-VLC; MH-VLC, Medium-High-VLC; H-VLC, High-VLC.






Figure 2. Fish sampled at the end of the experiment. (a) Fish with normal skeletal structures. (b) Fish with HD vertebrae under the dorsal fin (arrows). Affected vertebrae displayed a higher radiodensity than adjacent vertebrae, with some minor changes in shape.




Figure 3. CT analysis of Atlantic salmon (n = 10–15 fish per diet group). Ctr, Control; L-VLC, Low VLC; I-VLC, Intermediate VLC; MH-VLC, Medium-High VLC; H-VLC, High-VLC. Significance was set at  $P < 0.05$ . The letters a–c denotes significant differences between the groups.




Figure 4. Genes with known or possible roles in bone development. The heatmap presents fold changes compared with the control. Differential expressions are indicated by underlined bold italics. L-VLC, Low-VLC; I-VLC, Intermediate-VLC; MH-VLC, Medium-High-VLC; H-VLC, High-VLC.




Figure 5. Gene expression of the differentiation markers RUNX2, ALP, BGLAP, and COL1A1 in response to supplementation of VLC-PUFA or DHA. hFOB 1.19 cells were supplemented with VLC-PUFA or DHA (1 and 2  $\mu\text{M}$  of each, doses are presented combined). Total RNA was extracted and qPCR analysis for gene expression was performed. (a) Experiment 1. (b) Experiment 2. (c) Experiment 3. (d) Mean of experiments. Data are presented as mean  $\pm$  SEM. Comparisons were conducted using one-way ANOVA and Tukey HSD test. The significance level was set to  $P < 0.05$ .




Figure 6. Cytokine expression of growth medium from hFOB 1.19 cells cultured for gene expression analysis of differentiation markers. Data are presented as mean  $\pm$  SEM [2–6 replicates in batch 1 (B1)].

Table 1. Fatty acid composition of VLC-PUFA concentrates. \*

	VLC-PUFA concentrate in salmon feed (%)	VLC-PUFA concentrate in cell culture trials (%)
26:0	0.19	nd
<b>Sum of SFAs</b>	<b>0.19</b>	<b>nd</b>
22:1 <i>n</i> -9	0.33	nd
22:1 <i>n</i> -11	3.37	nd
24:1 <i>n</i> -9	2.69	1.29
26:1 <i>n</i> -9	0.20	2.97
<b>Sum of MUFAs</b>	<b>6.59</b>	<b>4.26</b>
22:5 <i>n</i> -6	0.37	nd
<b>Sum of <i>n</i>-6 PUFAs</b>	<b>0.37</b>	<b>nd</b>
18:4 <i>n</i> -3	0.20	nd
20:5 <i>n</i> -3	0.34	nd
22:5 <i>n</i> -3	4.30	0.20
22:6 <i>n</i> -3	13.29	0.68
<b>Sum of <i>n</i>-3 LC-PUFAs</b>	<b>18.13</b>	<b>0.88</b>
24:4 <i>n</i> -3	1.25	0.33
24:5 <i>n</i> -3	6.57	1.47
24:6 <i>n</i> -3	3.02	0.47
26:3 <i>n</i> -3	0.20	nd
26:4 <i>n</i> -3	1.97	nd
26:5 <i>n</i> -3	3.05	4.34
26:6 <i>n</i> -3	7.24	9.56
26:7 <i>n</i> -3	1.07	0.95
28:5 <i>n</i> -3	0.71	2.04
28:6 <i>n</i> -3	2.59	5.31
28:7 <i>n</i> -3	0.93	1.42
28:8 <i>n</i> -3	31.31	62.25
32:8 <i>n</i> -3	0.28	nd
<b>Sum of 30:5, 30:6, 30:8 fatty acids</b>	<b>2.53</b>	<b>5.03</b>
<b>Sum of <i>n</i>-3 VLC-PUFAs</b>	<b>62.72</b>	<b>93.17</b>
<b>Sum of VLC-FAs</b>	<b>65.61</b>	<b>97.43</b>
<b>Total</b>	<b>88.27</b>	<b>98.31</b>

Data are presented as percentage of total fatty acids.

ND, not detected; SFAs, saturated fatty acids; MUFAs, monounsaturated fatty acids; PUFAs, polyunsaturated fatty acids; VLC-PUFAs, very-long-chain polyunsaturated fatty acids.

\*The analytical methods used detect fatty acids  $\leq$ C30.

Table 2. Ingredient composition and PUFA content of the basal diet.

	Diet groups				
	Ctr	L-VLC	I-VLC	MH-VLC	H-VLC
<b>Composition of basal mix (%)</b>					
Fish meal *	50.00	50.00	50.00	50.00	50.00
Soy protein concentrate †	10.00	10.00	10.00	10.00	10.00
Wheat gluten ‡	9.00	9.00	9.00	9.00	9.00
Wheat §	13.11	13.11	13.11	13.11	13.11
Choline chloride	0.50	0.50	0.50	0.50	0.50
Canola lecithin ¶	0.50	0.50	0.50	0.50	0.50
Micro ingredients #	3.01	3.01	3.01	3.01	3.01
Water adjustment	-0.32	-0.32	-0.32	-0.32	-0.32
<b>Oils coated onto the basal diet mix</b>					
Fish oil (Herring oil, Nofima) **	13.83	13.04	12.25	11.45	10.66
VLC-PUFA ††		0.80	1.59	2.39	3.18
EPA/DHA (EPAX 6015 TGN) ††		0.09	0.18	0.27	0.36
EPA/DHA (EPAX 0460 TGN) ††	0.37	0.28	0.19	0.09	
SUM	100.00	100.00	100.00	100.00	100.00
<b>LC-PUFA and VLC-PUFA content</b>					
EPA, % of diet	1.17	1.17	1.17	1.17	1.17
DHA, % of diet	1.65	1.65	1.65	1.65	1.65
EPA + DHA, % of diet	2.82	2.82	2.82	2.82	2.82
EPA + DHA, % of fatty acids	14.85	14.85	14.85	14.85	14.85
VLC-PUFA, % of diet	0.00	0.47	0.95	1.42	1.90
VLC-PUFA, % of fatty acids	0.00	2.50	5.00	7.50	10.00

Ctr, Control; L-VLC, Low-VLC; I-VLC, Intermediate-VLC; MH-VLC, Medium-High-VLC; H-VLC, High-VLC

\*Vedde AS (Norway)

† Agrokorn (Germany)

‡ Tereos Syrdal (France)

§ Norgesmøllene AS (Norway)

|| Vilomix (Norway)

¶ Marvesa Oil and Fats (Netherland)

# Normin (Norway), Provided per 100 g of feed: K, 80 mg; Mg, 75 mg; Zn, 12 mg; Fe, 6 mg; Mn, 3 mg; Cu, 0.6 mg; Se, 0.03 mg; vitamin D, 300 mg; vitamin E, 16 mg; thiamin, 2 mg; riboflavin, 3 mg; pyridoxine-HCl, 3 mg; vitamin C, 20 mg; calcium d-pantothenate, 6 mg; biotin, 0.11 mg; folic acid, 1 mg; niacin, 20.1 mg; cobalamin, 0.005 mg; vitamin K3, 2 mg.

\*\* Pelagia (Norway)

†† Epax Norway AS (Norway)



Table 3. Fatty acid composition of the experimental salmon diets.

	Diet groups				
	Ctr	L-VLC	I-VLC	MH-VLC	H-VLC
14:0	10.74	9.71	10.54	9.00	8.84
15:0	0.20	0.19	nd	0.63	0.18
16:0	22.46	20.69	22.83	19.97	19.60
17:0	0.33	0.29	1.33	0.29	0.25
18:0	2.57	2.40	2.42	2.25	2.22
20:0	0.29	nd	0.26	0.26	0.25
24:0	0.31	0.31	0.30	0.34	0.32
<b>Sum of SFAs</b>	<b>36.90</b>	<b>33.59</b>	<b>37.69</b>	<b>32.73</b>	<b>31.66</b>
14:1 <i>n</i> -5	0.57	0.58	1.35	0.56	0.45
15:1	0.35	0.31	0.36	0.34	0.27
16:1 <i>n</i> -7	8.28	6.90	7.48	6.61	7.00
16:1 <i>n</i> -5	0.75	0.68	0.85	0.68	0.20
17:1 <i>n</i> -7	0.60	0.55	0.79	0.55	0.47
18:1 <i>n</i> -7	3.12	2.97	3.10	2.86	2.82
18:1 <i>n</i> -9	21.27	19.34	20.12	18.65	18.36
18:1 <i>n</i> -11	0.81	0.14	0.75	0.68	0.35
19:1	0.26	0.20	0.24	0.24	0.23
20:1 <i>n</i> -7	19.09	17.66	16.95	16.00	17.21
20:1 <i>n</i> -11	4.14	3.82	4.06	3.71	3.65
22:1 <i>n</i> -7	0.88	0.82	0.85	0.80	0.78
22:1 <i>n</i> -9	3.19	3.10	1.54	2.50	2.54
22:1 <i>n</i> -11	28.58	26.33	26.32	24.58	24.22
24:1 <i>n</i> -9	1.74	1.74	1.99	1.99	1.98
<b>Sum of MUFAs</b>	<b>93.63</b>	<b>85.13</b>	<b>86.75</b>	<b>80.77</b>	<b>80.54</b>
16:2 <i>n</i> -6	0.62	0.55	0.54	0.55	0.52
18:2 <i>n</i> -6	7.18	6.77	7.82	7.43	7.32
18:3 <i>n</i> -6	0.24	0.22	0.24	0.20	0.20
20:2 <i>n</i> -6	0.38	0.34	0.36	0.32	0.32
20:4 <i>n</i> -6	0.55	0.55	0.62	0.60	0.60
22:4 <i>n</i> -6	0.57	0.53	0.54	0.48	0.48

<b>Sum of <i>n</i>-6 PUFAs</b>	<b>9.55</b>	<b>8.95</b>	<b>10.13</b>	<b>9.57</b>	<b>9.44</b>
16:2 <i>n</i> -3	0.57	0.51	0.53	0.48	0.40
20:4 <i>n</i> -3	1.14	0.78	2.22	1.43	nd
20:5 <i>n</i> -3	9.84	9.31	12.44	10.78	10.51
22:5 <i>n</i> -3	1.70	1.79	2.07	2.18	2.15
22:6 <i>n</i> -3	16.45	15.66	16.16	15.66	15.41
<b>Sum of <i>n</i>-3 PUFAs</b>	<b>31.85</b>	<b>30.01</b>	<b>35.55</b>	<b>32.49</b>	<b>30.40</b>
<b>Sum EPA/DHA</b>	<b>26.29</b>	<b>24.97</b>	<b>28.60</b>	<b>26.44</b>	<b>25.92</b>
24:4 <i>n</i> -3	0.09	0.25	0.23	0.28	0.33
24:5 <i>n</i> -3	0.57	0.87	1.30	1.71	2.05
24:6 <i>n</i> -3	0.17	0.33	0.52	0.73	0.91
26:4 <i>n</i> -3	0.06	0.15	0.30	0.43	0.52
26:5 <i>n</i> -3	0.04	0.20	0.40	0.62	0.76
26:6 <i>n</i> -3	0.05	0.43	0.88	1.37	1.75
28:8 <i>n</i> -3	0.17	1.70	3.44	5.56	6.88
<b>Sum of <i>n</i>-3 VLC-PUFAs</b>	<b>1.18</b>	<b>3.99</b>	<b>7.22</b>	<b>10.92</b>	<b>13.48</b>
<b>Fat %</b>	<b>21.99</b>	<b>22.46</b>	<b>22.54</b>	<b>22.50</b>	<b>22.29</b>

Data are presented as mg/g feed.

Ctrl, Control; L-VLC, Low-VLC; I-VLC, Intermediate-VLC; MH-VLC, Medium-High-VLC; H-VLC, High-VLC; ND, not detected.

Table 4. Primers used for qPCR (SYBR Green, Applied Biosystems).

Gene	Accession no.	Forward primer (5'-3')	Reverse primer (5'-3')	Amplification sizes (bp)	Efficiency (R <sup>2</sup> )
<i>GAP</i>	NM_002	ATCCCATCACCATCTT	AAATGAGCCCCAGCC	120	102%
<i>DH</i>	046.3	CCAGGAGC	TTCTCCAT		(0.98)
<i>MKI</i>	NM_002	AAATTTGCTTCTGGCC	TGTCACATTCAATAC	185	97%
<i>67</i>	417.5	TTCCC	CCCTTCCA		(0.99)
<i>MYB</i>	NM_002	CCAGCCACTTCCCTAA	CAGTGTCCACTGCTTT	151	100%
<i>L2</i>	466.4	CCG	GTGC		(0.99)
<i>CCN</i>	NM_031	CCTGCAGAAGAAGAC	GACTGCTTGCTCTTCC	132	98%
<i>B1</i>	966.4	CTGTGT	TCAAGT		(0.99)
<i>PCN</i>	NM_002	CTTCCCTTACGCAAGT	TTGAGTGCCTCCAAC	188	110%
<i>A</i>	592.2	CTCAG	ACCTT		(0.99)
<i>EF1</i>	NM_001	GACACGTAGATTCGG	CCATCTCAGCAGCCT	107	95%
<i>A</i>	402.5	GCAAGTCCA	CCTTCTCAA		(0.98)
<i>RPO</i>	NM_000	GCGCAATGAGCAGAA	ACTTCTGCATGGCAC	121	98%
<i>L2</i>	937.4	CGGCG	GGGGC		(0.99)

Table 5. Probes used for qPCR (TaqMan, ThermoFisher).

Gene	Probe number
<i>RUNX2</i>	Hs00231692_m1
<i>ALP</i>	Hs00758162_m1
<i>BGLAP (OCN)</i>	Hs00609452_g1
<i>COL1a1</i>	Hs01028970_m1
<i>B2M</i>	Hs00187842_m1
<i>DKK1</i>	Hs00183740_m1
<i>AXIN2</i>	Hs00610344_m1

Table 6. Mean body weights and growth rates of salmon fed the experimental diets.

	Diet groups										P-value
	Ctr		L-VLC		I-VLC		MH-VLC		H-VLC		
	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	
BW (g) start	5.71	0.01	5.75	0.02	5.72	0.01	5.76	0.01	5.73	0.02	0.24
BW (g) end	17.53	0.03	17.33	0.03	17.23	0.15	17.1	0.20	17.13	0.20	0.28
SGR	3.13	0.33	3.06	0.04	3.05	0.03	3.05	0.05	3.03	0.06	0.55
TGC	1.73	0.02	1.69	0.02	1.69	0.02	1.68	0.03	1.67	0.04	0.55

n = 3 tanks, 100 fish per tank per diet group.

Ctr, Control; L-VLC, Low VLC; I-VLC, Intermediate VLC; MH-VLC, Medium-High VLC; H-VLC, High VLC; BW, body weight; SEM, standard error of the mean; SGR, specific growth rate; TGC, thermal growth coefficient.

Table 7. Bioavailability of minerals (% of bioavailable minerals from the diet) in Atlantic salmon.

	Diet groups						
	Ctr		I-VLC		H-VLC		P-value
	Mean	SEM	Mean	SEM	Mean	SEM	
P	41.78	1.99	42.95	0.42	39.50	0.80	0.23
Mg	39.11	2.31	38.10	1.07	37.55	2.67	0.87
Zn	27.88 <sup>a</sup>	1.29	21.72 <sup>b</sup>	0.47	21.11 <sup>b</sup>	1.31	0.01
DM	15.10	0.21	14.20	0.23	13.70	0.38	0.04

Data are presented as mean  $\pm$  standard error of mean (SEM).

Ctr, Control; I-VLC, Intermediate VLC; H-VLC, High VLC; P, phosphorus; Mg, magnesium; Zn, Zinc; DM, dry matter (% DM in faeces).

The letters a and b denote significant differences between the groups.

Table 8. Fatty acid composition of whole-body homogenate of Atlantic salmon.

	Diet groups										P-value (one-way ANOVA)
	Ctr		L-VLC		I-VLC		MH-VLC		H-VLC		
	Me an	SE M	Me an	SE M	Me an	SE M	Me an	SE M	Me an	SE M	
14:0	4.9 6	0.3 2	4.6 8	0.3 4	4.4 7	0.2 7	4.9 1	0.3 4	4.8 6	0.1 8	0.7684
15:0	0.2 7	0.0 9	0.3 6	0.0 2	0.3 4	0.0 2	0.3 7	0.0 2	0.3 7	0.0 1	0.4934
16:0	12. 59	0.8 1	13. 03	0.8 1	12. 73	0.6 1	13. 80	0.8 9	13. 63	0.3 6	0.7032
17:0	0.1 9	0.0 2	0.1 8	0.0 1	0.1 8	0.0 2	0.1 8	0.0 2	0.2 5	0.0 5	0.2395
18:0	2.0 3	0.4 0	2.3 8	0.1 5	2.3 2	0.0 7	2.4 6	0.1 8	2.6 2	0.1 0	0.4404
<b>Sum of SFAs</b>	<b>20. 36</b>	<b>1.1 7</b>	<b>20. 90</b>	<b>1.3 5</b>	<b>20. 31</b>	<b>1.0 0</b>	<b>21. 94</b>	<b>1.3 9</b>	<b>21. 97</b>	<b>0.6 1</b>	<b>0.7272</b>
16:1 <i>n</i> -7	4.2 4	0.2 5	4.2 6	0.3 0	4.3 2	0.3 7	4.6 7	0.3 7	4.4 2	0.1 9	0.8404
18:1 <i>n</i> -9	13. 19	1.5 0	14. 63	1.3 1	13. 56	0.8 8	14, 70	1.3 4	15. 14	0.6 5	0.7411
20:1 <i>n</i> -7	9.4 1	0.3 9	9.3 1	0.5 9	8.7 0	0.5 4	9.7 4	0.5 8	9.5 7	0.3 7	0.6642
20:1 <i>n</i> -11	1.7 5	0.1 5	1.5 7	0.0 9	1.5 3	0.0 5	1.6 6	0.0 9	1.6 4	0.0 6	0.5538
22:1 <i>n</i> -9	1.1 7	0.2 4	0.9 8	0.0 5	0.8 2	0.0 6	1.0 9	0.1 7	0.9 1	0.0 5	0.4411
22:1 <i>n</i> -11	12. 03	1.2 7	10. 63	0.6 0	10. 40	0.4 3	11. 21	0.5 4	11. 10	0.2 9	0.5645
24:1 <i>n</i> -9	0.6 8	0.2 9	0.4 2	0.2 6	0.4 2	0.2 5	0.7 3	0.2 9	0.7 0	0.2 6	0.8488
<b>Sum of MUFAs</b>	<b>46. 37</b>	<b>2.6 9</b>	<b>45. 27</b>	<b>4.8 3</b>	<b>44. 13</b>	<b>4.3 8</b>	<b>48. 21</b>	<b>5.2 5</b>	<b>47. 81</b>	<b>2.5 0</b>	<b>0.7200</b>
18:2 <i>n</i> -6	3.8 6	0.1 6	3.8 1	0.1 7	3.8 9	0.0 3	4.0 9	0.1 1	4.0 3	0.0 4	0.4388
18:3 <i>n</i> -6	0.1 5	0.0 2	0.1 5	0.0 1	0.1 7	0.0 0	0.1 6	0.0 2	0.1 7	0.0 0	0.9034
20:2 <i>n</i> -6	0.3 3	0.0 7	0.4 0	0.0 2	0.3 9	0.0 1	0.4 2	0.0 2	0.4 3	0.0 1	0.3725
20:3 <i>n</i> -6	0.1 7	0.0 1	0.1 8	0.0 2	0.1 6	0.0 1	0.1 8	0.0 2	0.1 7	0.0 0	0.8469
20:4 <i>n</i> -6	0.2	0.0	0.2	0.0	0.2	0.0	0.2	0.0	0.2	0.0	0.9545



	8	1	8	1	8	1	9	1	9	0	
22:4 <i>n</i> -6	0.2	0.0	0.3	0.0	0.2	0.0	0.2	0.0	0.3	0.0	0.6263
	5	4	1	2	8	1	8	5	2	1	
<b>Sum of <i>n</i>-6 PUFAs</b>	<b>4.9</b>	<b>0.1</b>	<b>5.1</b>	<b>0.1</b>	<b>5.0</b>	<b>0.1</b>	<b>5.3</b>	<b>0.2</b>	<b>5.4</b>	<b>0.0</b>	<b>0.3952</b>
18:3 <i>n</i> -3	1.0	0.0	0.9	0.0	0.9	0.0	1.0	0.0	1.0	0.0	0.5780
	2	2	7	5	7	1	3	5	1	2	
20:4 <i>n</i> -3	0.5	0.1	0.6	0.0	0.5	0.0	0.6	0.0	0.5	0.1	0.9570
	5	0	2	4	4	9	0	6	7	1	
20:3 <i>n</i> -3	0.1	0.0	0.1	0.0	0.1	0.0	0.1	0.0	0.1	0.0	0.8376
	3	0	2	1	2	0	2	0	3	0	
20:5 <i>n</i> -3	3.5	0.4	2.9	0.1	3.1	0.0	2.9	0.1	3.1	0.1	0.2803
	6	1	5	0	0	1	7	5	8	1	
22:5 <i>n</i> -3	1.2	0.2	0.9	0.0	1.1	0.1	1.3	0.2	1.3	0.1	0.5454
	5	2	3	3	5	6	1	1	1	9	
22:6 <i>n</i> -3	10.	1.1	11.	0.4	11.	0.2	11.	0.4	11.	0.3	0.3315
	04	4	19	0	15	0	68	1	74	0	
<b>Sum of <i>n</i>-3 PUFAs</b>	<b>16.</b>	<b>1.0</b>	<b>17.</b>	<b>0.6</b>	<b>17.</b>	<b>0.5</b>	<b>17.</b>	<b>0.4</b>	<b>18.</b>	<b>0.3</b>	<b>0.4598</b>
	<b>75</b>	<b>1</b>	<b>00</b>	<b>0</b>	<b>06</b>	<b>0</b>	<b>90</b>	<b>6</b>	<b>16</b>	<b>0</b>	
<b>Sum EPA/DHA</b>	<b>13.</b>	<b>0.7</b>	<b>14.</b>	<b>0.5</b>	<b>14.</b>	<b>0.2</b>	<b>14.</b>	<b>0.3</b>	<b>14.</b>	<b>0.3</b>	<b>0.3952</b>
	<b>61</b>	<b>4</b>	<b>14</b>	<b>0</b>	<b>25</b>	<b>0</b>	<b>65</b>	<b>9</b>	<b>92</b>	<b>7</b>	
<b>Sum others*</b>	<b>4.4</b>	<b>0.2</b>	<b>3.9</b>	<b>0.5</b>	<b>4.5</b>	<b>0.1</b>	<b>4.9</b>	<b>0.4</b>	<b>4.9</b>	<b>0.1</b>	<b>0.3684</b>
	<b>5</b>	<b>8</b>	<b>9</b>	<b>6</b>	<b>5</b>	<b>9</b>	<b>2</b>	<b>7</b>	<b>9</b>	<b>4</b>	
<b>SUM FA</b>	<b>91.</b>	<b>3.3</b>	<b>93.</b>	<b>4.7</b>	<b>91.</b>	<b>3.0</b>	<b>97.</b>	<b>5.3</b>	<b>97.</b>	<b>2.7</b>	<b>0.6918</b>
	<b>80</b>	<b>5</b>	<b>26</b>	<b>3</b>	<b>81</b>	<b>6</b>	<b>52</b>	<b>9</b>	<b>81</b>	<b>4</b>	

Data are presented as mg/g tissue.

Ctrl, Control; L-VLC, Low-VLC; I-VLC, Intermediate-VLC; MH-VLC, Medium-High-VLC; H-VLC, High-VLC.

\*Others include 20:0, 24:0, 14:1 *n*-5, 15:1, 16:1 *n*-5, 17:1 *n*-7, 18:1 *n*-7, 19:1, 22:1 *n*-7, 16:2 *n*-6, 16:2 *n*-3.

Table 9. Mineral composition of Atlantic salmon skin.

	Ctr		L-VLC		I-VLC		MH-VLC		H-VLC		P-value
	Mean	SEM	Mean	SEM	Mean	SE M	Mean	SE M	Mean	SE M	
P	10,13 3	867	11,00 0	577	11,66 7	333	10,66 7	333	13,00 0	577	0.02 *
Ca	15,33 3	1,66 7	17,00 0	1,15 5	17,66 7	882	17,33 3	667	20,33 3	882	0.01 *
Mg	453	33	467	17	490	15	487	23	540	32	0.02 *
Zn	47	6	51	1	51	2	49	4	56	6	0.21

Data are presented as mg/kg. P-value is of linear regression analysis.

Ctr, Control; L-VLC, Low-VLC; I-VLC, Intermediate-VLC; MH-VLC, Medium-High-VLC; H-VLC, High-VLC; P, phosphorus; Ca, calcium; Mg, magnesium; Zn, zinc.

Table 10. Mineral composition of Atlantic salmon vertebrae.

	Ctr		L-VLC		I-VLC		MH-VLC		H-VLC		
	Mean	SE M	Mean	SEM	Mean	SEM	Mean	SEM	Mean	SE M	P- value
P	18,00 0	0	18,66 7	1,33 3	18,33 3	882	19,00 0	1,528	22,00 0	0	0.02 *
Ca	32,33 3	667	33,00 0	3,00 0	32,66 7	1,66 7	34,33 3	32,82 3	40,33 3	333	0.02 *
Mg	603	7	607	30	620	15	627	20	690	6	0.01 *
Zn	140	26	127	15	140	12	123	13	173	26	0.29

Data are presented as mg/kg. P-value is of linear regression analysis.

Ctr, Control; L-VLC, Low-VLC; I-VLC, Intermediate-VLC; MH-VLC, Medium-High-VLC; H-VLC, High-VLC; P, phosphorus; Ca, calcium; Mg, magnesium; Zn, zinc.

Table 11. Fatty acid composition of hFOB cells.

	Control		2 $\mu$ M DHA		2 $\mu$ M VLC- PUFA		P-value (one-way ANOVA)
	Mean	SE M	Mean	SE M	Mean	SEM	
14:0	37.3	3.02	38.3	2.23	41.8	1.79	0.4331
16:0	642.8	4.6	648.5	40.4	626.7	22.2	0.8401
17:0	13.4	0.3	12.5	0.7	12.5	0.5	0.4179
18:0	316.7	8.1	315.8	20.2	304.2	7.7	0.7698
20:0	11.1	0.2	10.1	0.6	10.1	0.4	0.2270
22:0	8.3	0.1	7.3	0.8	8.3	0.3	0.2975
<b>Sum of SFAs</b>	<b>1040.6</b>	<b>0.9</b>	<b>1045.0</b>	<b>58.6</b>	<b>1019.8</b>	<b>32.3</b>	<b>0.8878</b>
18:1 <i>n</i> -7	141.0	2.4	135.0	5.8	134.6	3.1	0.4985
18:1 <i>n</i> -9	573.7	10.5	554.6	19.9	546.5	14.1	0.4789
20:1 <i>n</i> -9	19.3	0.4	16.2	2.6	18.3	0.4	0.3994
20:1 <i>n</i> -11	5.8	0.4	7.1	1.1	7.6	1.5	0.4990
24:1 <i>n</i> -9	3.9	2.0	3.9	2.0	5.9	0.2	0.6398
<b>Sum of MUFAs</b>	<b>907.7</b>	<b>12.7</b>	<b>871.5</b>	<b>30.9</b>	<b>831.9</b>	<b>45.2</b>	<b>0.3255</b>
16:2 <i>n</i> -6	47.7	10.4	52.5	3.0	49.1	3.7	0.8640
18:2 <i>n</i> -6	41.9	0.8	40.6	1.5	41.4	1.2	0.7394
18:3 <i>n</i> -6	12.4	0.7	11.5	1.1	11.9	1.1	0.8032
20:2 <i>n</i> -6	19.0	0.3	18.8	0.8	17.3	0.5	0.1299
20:3 <i>n</i> -6	21.9	0.2	20.6	0.9	22.0	0.6	0.2916
20:4 <i>n</i> -6	78.8	1.3	106.7	30.3	76.9	2.0	0.4535
22:4 <i>n</i> -6	13.7	0.3	13.7	0.5	14.4	0.5	0.4756
<b>Sum of <i>n</i>-6 PUFAs</b>	<b>197.6</b>	<b>18.0</b>	<b>226.2</b>	<b>42.3</b>	<b>211.0</b>	<b>7.7</b>	<b>0.7633</b>
20:4 <i>n</i> -3	9.1	0.3	8.8	1.3	7.1	0.5	0.2897
20:5 <i>n</i> -3	18.7 <sup>a</sup>	0.4	19.3 <sup>ab</sup>	0.7	21.7 <sup>b</sup>	0.6	0.0232*
22:5 <i>n</i> -3	27.2	0.4	26.2	0.8	26.9	1.5	0.8063

22:6 <i>n</i> -3	75.5 <sup>a</sup>	1.0	96.3 <sup>c</sup>	2.7	84.8 <sup>b</sup>	2.1	0.0013*
<b>Sum of <i>n</i>-3 PUFAs</b>	<b>142.3<sup>a</sup></b>	<b>3.3</b>	<b>164.0<sup>a</sup><sub>b</sub></b>	<b>5.1</b>	<b>173.6<sup>b</sup></b>	<b>8.3</b>	<b>0.0248*</b>
<b>SUM EPA/DHA</b>	<b>94.2<sup>a</sup></b>	<b>1.4</b>	<b>115.6<sup>b</sup></b>	<b>3.4</b>	<b>106.5<sup>b</sup></b>	<b>2.7</b>	<b>0.0036*</b>
24:6 <i>n</i> -3	49.3	4.2	56.5	1.8	62.2	7.1	0.2466
24:5 <i>n</i> -3	67.4	4.1	76.5	3.7	84.5	11.3	0.3161
26:6 <i>n</i> -3	2.6 <sup>a</sup>	0.2	3.3 <sup>ab</sup>	0.3	6.7 <sup>b</sup>	1.5	0.0389*
26:5 <i>n</i> -3	1.1 <sup>a</sup>	0.2	1.7 <sup>ab</sup>	0.5	4.6 <sup>b</sup>	1.2	0.0304*
28:8 <i>n</i> -3	0.0 <sup>a</sup>	0.0	0.0 <sup>a</sup>	0.0	11.8 <sup>b</sup>	2.6	0.0022*
<b>SUM FA</b>	<b>2635.3</b>	<b>55.8</b>	<b>2670.3</b>	<b>63.7</b>	<b>2672.8</b>	<b>73.6</b>	<b>0.9021</b>
<b>Sum others<sup>†</sup></b>	<b>180.4</b>	<b>3.9</b>	<b>168.3</b>	<b>25.8</b>	<b>186.7</b>	<b>10.1</b>	<b>0.7292</b>

Data are presented as µg/g sample (n = 3).

\* Indicates significant difference (P < 0.05).

† Included in others 15:0, 15:1, 16:1 *n*-7, 16:1 *n*-5, 17:1 *n*-7, 18:1 *n*-11, 20:1 *n*-7, 16:2 *n*-3, 18:4 *n*-3.